Meeting
2018 ASCO Annual Meeting
A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.
Authors
Anabel Beatriz Sanchez-Spitman
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands
Anabel Beatriz Sanchez-Spitman , Vincent O. Dezentjé , Jesse J Swen , Dirk Jan A.R. Moes , Erdogan Batman , Carolien H. Smorenburg , Lynn Jongen , Maartje Los , Patrick Neven , Hans Gelderblom , Henk-jan Guchelaar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NTR1509
Citation
J Clin Oncol 36, 2018 (suppl; abstr 523)
DOI
10.1200/JCO.2018.36.15_suppl.523
Abstract #
523
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.
First Author: Anneleen Lintermans
Poster
2014 ASCO Annual Meeting
Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial.
First Author: Shahbal Bill Kangarloo
Poster
2013 ASCO Annual Meeting
Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.
First Author: Peter Fox
Poster
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
First Author: Bavanthi Balakrishnar